Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (912)	11/13/1997 11:55:00 PM
From: Steve Harmon	Read Replies (2) \| Respond to of 2742

To all CIST shareholders, The recent move by CIST's mgt. of adding Stephen Simes to the board of directors was a good one. Simes was the former CEO of Gynex Pharmacuetical from 1991 to 1994. While at Gynex he developed Biotechnology General's(BTGC) red-hot new product OXANDRIN. Simes also did a tremendous job in increasing shareholder value a GYNX.>>>>>>>>> When Simes became CEO of Gynex in 1991>>>>>>>>>> Gynex's stock price was trading at 1/4 BTGC bought Gynex in 1993 for $3.50 a share. GOOD MOVE